Core Viewpoint - Kangde (Shenzhen) Biotechnology Co., Ltd. has officially passed the ISO13485:2016 international certification for medical device quality management systems, indicating that the company's quality management capabilities in the research, production, and service of cancer detection in vitro diagnostic reagents have reached international standards, enabling the continuous provision of reliable products and services to global customers [1][3][4] Group 1 - ISO13485 certification is recognized as the "gold standard" in the medical device industry, covering the entire lifecycle of product design, production, storage, sales, and after-sales service, with an emphasis on risk control and traceability [3] - The World Health Organization states that approximately one-third of cancers can be completely prevented, one-third can be cured through early detection, and one-third can be managed with medical measures to prolong life and alleviate suffering, highlighting the importance of early cancer screening and diagnosis [3] - Effective and reliable early cancer detection in vitro diagnostic reagent technology addresses the clinical challenge of late-stage cancer diagnosis, where most patients are diagnosed at advanced stages, missing the optimal treatment window [3] Group 2 - The successful ISO13485 certification represents a significant milestone in establishing a comprehensive quality management system for Kangde (Shenzhen) Biotechnology Co., Ltd., marking an upgrade in the company's quality management level [4] - The certification serves as strong evidence of the company's adherence to international standards in research, production, and sales, ensuring product safety and effectiveness [4] - The company is committed to empowering the field of precision cancer diagnosis with high-quality technology and products, reflecting its mission and dedication to advancing human health [4]

Group 1 - The 2025 Guangdong Urology Academic Conference and Bladder Cancer Academic Conference was successfully held in Shenzhen from August 15-17, 2025, showcasing advancements in early screening for tumors [1] - The UriFind® product by Benchmark Medical was highlighted as an innovative leader in the field of early screening for urinary tract cancers, receiving significant attention from experts [1] - Clinical research involving 1,172 samples demonstrated that the UriFind® kit has a sensitivity of 89.74%, specificity of 92.46%, and accuracy of 91.47% for assisting in the diagnosis of urinary tract cancers [1] Group 2 - Benchmark Medical, a subsidiary of Kangsheng Global Medical Testing Group, focuses on utilizing tumor DNA methylation sequencing technology for early cancer diagnosis and screening [5] - The company has developed products targeting over 70% of high-incidence cancers, including lung, breast, digestive system, and urinary system cancers, covering the entire process from early screening to diagnosis and monitoring [5] - Benchmark Medical has also created a big data and artificial intelligence platform centered on early screening, diagnosis, and treatment of lung cancer [5]

Core Viewpoint - The "Pink Cradle" public welfare initiative aims to systematically explore the collaborative innovation of cancer prevention and reproductive rights protection in China, starting with breast cancer prevention and treatment [1][10]. Group 1: Cancer Prevention and Reproductive Rights - Breast cancer, known as the "pink killer," is one of the most common malignant tumors threatening women's health in China, with 357,200 new cases reported in 2022, accounting for 15.6% of all new cancer cases among women [2]. - Over 50% of young breast cancer patients express a desire for childbirth, yet the pregnancy rate is less than 5%, indicating a significant conflict between treatment needs and reproductive desires that requires systematic resolution [2]. - The "Healthy China Action - Cancer Prevention Action Implementation Plan (2023-2030)" emphasizes the need for comprehensive health management for cancer patients, while recent government measures aim to create a supportive environment for childbirth [2]. Group 2: Collaborative Efforts and Initiatives - The "China Cancer Early Screening and Diagnosis Public Welfare Action" was launched to establish a nationwide screening network for high-risk early-onset breast cancer patients and to create a multidisciplinary collaborative treatment model [4][6]. - The initiative seeks to integrate innovative screening technologies with the construction of a reproductive-friendly society, enhancing public awareness of reproductive health protection for cancer patients [4][10]. - The establishment of a cancer reproductive protection network involves collaboration among various disciplines, including oncology, reproductive medicine, psychology, and genetics, to improve the quality of life and survival rates for patients [6]. Group 3: Educational and Supportive Measures - The initiative includes training for medical personnel and media to enhance their capabilities in cancer reproductive health education, as well as the establishment of care stations in community hospitals [9]. - A comprehensive knowledge base will be created to support breast cancer treatment and reproductive protection, focusing on public engagement through educational materials and emotional resonance [9]. - The project aims to reshape public perception regarding the coexistence of cancer survival and reproductive health, promoting a dual focus on patient rights and quality of life [9][10].

Core Viewpoint - The 31st National Cancer Prevention and Control Publicity Week aims to promote cancer prevention knowledge and encourage healthy lifestyles to reduce cancer risk factors, particularly focusing on early screening and standardized treatment for cancer patients [1] Group 1: Cancer Statistics and Risk Factors - Lung cancer is the leading cause of cancer incidence and mortality in China, with 1.0606 million new cases and 733,300 deaths reported in 2022, accounting for 22.0% and 28.5% of all cancer cases and deaths respectively [2] - Approximately 80% to 90% of lung cancer cases are linked to smoking, with air pollution and occupational exposure also being significant risk factors [2][3] - High-risk groups for lung cancer include smokers, individuals over 45 years old, those with a history of chronic lung diseases, and people exposed to carcinogens like asbestos [4] Group 2: Screening and Early Detection - Chest CT screening is the primary method for early detection of lung cancer, with low-dose spiral CT significantly improving early detection rates [5] - Public awareness campaigns are essential to educate about lung cancer risk factors and symptoms, aiming to reduce unnecessary panic over lung nodules [3][5] - High-risk individuals should undergo regular screening to identify potential risks early [4] Group 3: Treatment Approaches - Lung cancer treatment is becoming more personalized, with a focus on comprehensive management to improve survival rates and quality of life [6] - Non-small cell lung cancer (NSCLC) accounts for over 80% of cases, with surgical resection being the standard treatment for early-stage patients, while advanced stages may require chemotherapy and targeted therapies [6][7] - Small cell lung cancer (SCLC) treatment often involves chemotherapy, with an emphasis on preventing metastasis [7] Group 4: Follow-Up Care - Regular follow-up is crucial for monitoring patient health and adjusting treatment strategies, with specific schedules based on cancer stage and treatment response [9][11] - Advanced monitoring techniques, such as ctDNA testing, are being integrated into follow-up care to detect recurrence earlier [10] - Follow-up frequency varies, with high-risk patients requiring more frequent assessments to ensure timely intervention [11]